Jubilant Pharmo

how big is Jubilant Pharmo?

As of Jun 06, Jubilant Pharmova Ltd has a market capitalization of 18,271.94 Cr, with recent net sales of 7,234.50 Cr and a net profit of 839.40 Cr for the latest four quarters.

Market Cap: As of Jun 06, Jubilant Pharmova Ltd has a market capitalization of 18,271.94 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported a sum of Net Sales of 7,234.50 Cr and a sum of Net Profit of 839.40 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds are valued at 5,433.90 Cr, and the Total Assets amount to 11,315.80 Cr.

Who are in the management team of Jubilant Pharmo?

As of March 2023, the management team of Jubilant Pharmo includes Shyam S Bhartia (Chairman), Hari S Bhartia (Co-Chairman), Priyavrat Bhartia (Managing Director), and Arjun Shanker Bhartia (Joint Managing Director), along with several non-executive and independent directors. This diverse team oversees the company's governance and strategic direction.

As of March 2023, the management team of Jubilant Pharmo includes the following individuals:<BR><BR>1. Shyam S Bhartia - Chairman (Non-Executive)<BR>2. Hari S Bhartia - Co-Chairman & Non-Executive Director<BR>3. S Sridhar - Non-Executive & Independent Director<BR>4. Sudha Pillai - Non-Executive & Independent Director<BR>5. Ashok Misra - Non-Executive & Independent Director<BR>6. Vivek Mehra - Non-Executive & Independent Director<BR>7. Sushil Kumar Roongta - Non-Executive & Independent Director<BR>8. Priyavrat Bhartia - Managing Director<BR>9. Arjun Shanker Bhartia - Joint Managing Director<BR>10. Arun Seth - Non-Executive & Independent Director<BR>11. Arvind Chokhany - Whole Time Director & CFO<BR>12. Naresh Kapoor - Company Secretary & Compliance Officer<BR>13. R Kumar - Whole Time Director<BR>14. Shirish Gundopant Belapure - Independent Director<BR><BR>This diverse team includes both executive and non-executive members, contributing to the governance and strategic direction of the company.

What does Jubilant Pharmo do?

Jubilant Pharmova Ltd is a mid-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of ₹1,929 Cr and a net profit of ₹154 Cr for March 2025. The company, formerly known as Jubilant Life Sciences, has a market cap of ₹18,236 Cr and key metrics including a P/E ratio of 38.00 and a dividend yield of 0.44%.

Overview:<BR>Jubilant Pharmova Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History:<BR>The company was initially incorporated as 'Vam Organic Chemicals Limited' in 1978. It underwent several name changes, becoming 'Jubilant Organosys Limited' in November 2001, 'Jubilant Life Sciences Limited' in October 2009, and finally 'Jubilant Pharmova Limited' in February 2021. The most recent quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,929 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 154 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 18,236 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 38.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.44%<BR>- Debt Equity: 0.26<BR>- Return on Equity: 7.75%<BR>- Price to Book: 2.92<BR><BR>Contact Details:<BR>- Address: Bhartiagram Gajraula, Amroha Uttar Pradesh: 244223<BR>- Phone: 91-5924-267200<BR>- Email: investors@jubl.com/support@jubl.com<BR>- Website: http://www.jubilantpharmova.com

Has Jubilant Pharmo declared dividend?

Yes, Jubilant Pharmova Ltd has declared a 500% dividend, amounting to ₹5 per share, with an ex-date of August 2, 2024. The company has shown strong total returns over longer periods, despite some short-term fluctuations.

Jubilant Pharmova Ltd has declared a 500% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 500%<BR>- Amount per share: 5 per share<BR>- Ex-date: 02 Aug 2024<BR><BR>Dividend Yield: 0.44%.<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -5.83%, the dividend return was 0%, resulting in a total return of -5.83%.<BR><BR>For the 1 year period, the price return was 58.16%, the dividend return was 0.68%, leading to a total return of 58.84%.<BR><BR>Over the 2 years period, the price return was 235.09%, the dividend return was 2.44%, culminating in a total return of 237.53%.<BR><BR>In the 3 years period, the price return was 185.02%, the dividend return was 4.65%, which resulted in a total return of 189.67%.<BR><BR>During the 4 years period, the price return was 36.31%, the dividend return was 2.71%, giving a total return of 39.02%.<BR><BR>For the 5 years period, the price return was 98.97%, the dividend return was 2.94%, resulting in a total return of 101.91%.<BR><BR>Overall, Jubilant Pharmova Ltd has declared a significant dividend, and the total returns over various periods show a positive trend, particularly in the longer terms, indicating strong performance despite some short-term fluctuations.

Who are the peers of the Jubilant Pharmo?

Jubilant Pharmo's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Concord Biotech, Caplin Point Lab, Blue Jet Health, Natco Pharma, and Sai Life. In terms of management risk, growth, and capital structure, Jubilant Pharmo is rated average, while its 1-year return of 68.61% is higher than Natco Pharma's but lower than Blue Jet Health's 139.69%.

Peers: The peers of Jubilant Pharmo are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Concord Biotech, Caplin Point Lab, Blue Jet Health, Natco Pharma, and Sai Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Concord Biotech, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Caplin Point Lab, Blue Jet Health, Natco Pharma, and Sai Life, and Average management risk is noted for Jubilant Pharmo. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest have Below Average or Good growth ratings, with Divi's Lab. showing Below Average growth, and Concord Biotech showing Good growth. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Concord Biotech, and Caplin Point Lab, while Good is noted for Torrent Pharma, and Average for Jubilant Pharmo.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Blue Jet Health at 139.69%, while Natco Pharma has the lowest at -13.50%. Jubilant Pharmo's 1-year return of 68.61% is significantly higher than Natco Pharma's but lower than Blue Jet Health's. Additionally, Natco Pharma and Concord Biotech have negative six-month returns.

Who are the top shareholders of the Jubilant Pharmo?

The top shareholders of Jubilant Pharma include Spb Trustee Company Pvt Ltd with 20.52%, 18 mutual fund schemes holding 3.66%, 151 foreign institutional investors at 17.22%, and East Bridge Capital Master Fund I Ltd as the largest public shareholder with 4.3%. Individual investors collectively own 17.75% of the shares.

The top shareholders of Jubilant Pharma include a mix of promoters and institutional investors. The majority shareholders are the promoters, with Spb Trustee Company Pvt Ltd holding the largest stake at 20.52%. <BR><BR>In terms of institutional holdings, 18 mutual fund schemes collectively hold 3.66% of the company, while 151 foreign institutional investors (FIIs) account for 17.22%. The highest public shareholder is East Bridge Capital Master Fund I Ltd, which holds 4.3%. Additionally, individual investors collectively own 17.75% of the shares.

Is Jubilant Pharmo overvalued or undervalued?

As of November 3, 2025, Jubilant Pharma is fairly valued with a PE ratio of 37.37 and an EV to EBITDA of 14.49, positioned between peers like Sun Pharma and Cipla, despite facing challenges with an -8.16% return over the past year.

As of 3 November 2025, the valuation grade for Jubilant Pharmo has moved from attractive to fair. The company is currently fairly valued, with a PE ratio of 37.37, an EV to EBITDA of 14.49, and a PEG ratio of 1.35. In comparison to its peers, Sun Pharma has a PE ratio of 35.62 and an EV to EBITDA of 24.18, while Cipla shows a more attractive PE of 22.44 and an EV to EBITDA of 5.66, indicating that Jubilant Pharmo is positioned in the middle range of its industry.<BR><BR>Despite recent stock performance showing a 4.09% gain over the past week compared to a -0.94% decline in the Sensex, the company's longer-term returns, particularly a -8.16% return over the past year, suggest some challenges ahead. Overall, the current valuation reflects a balance between growth expectations and market realities, placing Jubilant Pharmo in a fair valuation category amidst its peers.

How has been the historical performance of Jubilant Pharmo?

Jubilant Pharmo's historical performance shows fluctuating financial metrics, with net sales increasing from INR 6,130.16 crore in March 2022 to INR 7,234.50 crore in March 2025, despite a peak of INR 9,110.82 crore in March 2019. The company has rebounded in profitability, with profit after tax rising to INR 836.80 crore in March 2025 from a loss of INR 77.13 crore in March 2023.

Answer:<BR>The historical performance of Jubilant Pharmo shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Jubilant Pharmo's net sales have shown a steady increase from INR 6,130.16 crore in March 2022 to INR 7,234.50 crore in March 2025. However, this is a decline from the peak of INR 9,110.82 crore in March 2019. The total operating income followed a similar trend, reaching INR 7,234.50 crore in March 2025. The total expenditure, excluding depreciation, increased from INR 4,973.83 crore in March 2022 to INR 6,060.80 crore in March 2025. Operating profit (PBDIT) has fluctuated, peaking at INR 1,739.01 crore in March 2019 and dropping to INR 1,230.50 crore in March 2025. Profit before tax saw a significant recovery to INR 981.10 crore in March 2025, up from just INR 15.53 crore in March 2023. Profit after tax also rebounded to INR 836.80 crore in March 2025, compared to a loss of INR 77.13 crore in March 2023. The company's total assets increased from INR 9,829.60 crore in March 2022 to INR 12,499.00 crore in March 2025, while total liabilities rose from INR 9,829.60 crore to INR 12,499.00 crore in the same period. Cash flow from operating activities improved to INR 1,072.00 crore in March 2025, indicating a positive trend in cash generation. Overall, Jubilant Pharmo has demonstrated resilience with a recovery in profitability and growth in sales, despite facing challenges in previous years.

Is Jubilant Pharmo technically bullish or bearish?

As of December 3, 2025, Jubilant Pharma's technical trend has shifted to a bearish outlook, supported by mildly bearish MACD and KST indicators, alongside mixed signals from moving averages and Bollinger Bands.

As of 3 December 2025, the technical trend for Jubilant Pharmo has changed from mildly bullish to sideways. The current technical stance is bearish, with key indicators supporting this view. The MACD is mildly bearish on both the weekly and monthly time frames, and the KST also shows a mildly bearish trend. The Bollinger Bands indicate a bearish sentiment on the weekly chart, while the moving averages on the daily chart are mildly bullish, suggesting mixed signals. Overall, the weakness in the weekly indicators and the sideways trend suggest a bearish outlook with limited strength.

When is the next results date for Jubilant Pharmova Ltd?

The next results date for Jubilant Pharmova Ltd is February 6, 2026.

The next results date for Jubilant Pharmova Ltd is scheduled for February 6, 2026.

Are Jubilant Pharmova Ltd latest results good or bad?

Jubilant Pharmova Ltd's latest results show a 16.51% revenue growth to ₹2,122.50 crores, but a concerning 44.60% decline in net profit to ₹55.90 crores and a significant drop in operating margin indicate serious financial challenges, making the overall results unfavorable.

Jubilant Pharmova Ltd's latest results indicate a challenging quarter for the company. While it achieved a significant revenue growth of 16.51% year-on-year, reaching ₹2,122.50 crores, this positive top-line performance was overshadowed by a dramatic decline in net profit. The net profit fell by 44.60% year-on-year to ₹55.90 crores, which raises concerns about the company's profitability and operational efficiency.<BR><BR>The operating margin also contracted sharply, dropping to 13.68% from 17.44% in the previous quarter, indicating significant cost pressures. This margin compression, coupled with a high tax rate of 40.26%, has led to a profit after tax margin of only 2.64%, the lowest since Q4 FY24.<BR><BR>Overall, while the revenue growth is a positive sign, the substantial profit decline and operational challenges suggest that the company's financial health is under severe pressure. Therefore, the results can be characterized as bad, reflecting deeper issues that need to be addressed for sustainable growth.

Should I buy, sell or hold Jubilant Pharmova Ltd?

Why is Jubilant Pharmova Ltd falling/rising?

As of 23-Mar, Jubilant Pharmova Ltd's stock price is at 814.20, reflecting a 2.12% decrease and a significant decline of 24.24% year-to-date. The stock is underperforming the market, trading below all key moving averages, and is close to its 52-week low, indicating a negative outlook amid poor long-term growth and declining profits.

As of 23-Mar, Jubilant Pharmova Ltd's stock price is falling, currently at 814.20, which reflects a decrease of 17.6 or 2.12%. The stock has been on a downward trend, having lost 5.45% over the last three days and is currently trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, the stock is close to its 52-week low, just 3.24% away from Rs 783.75.<BR><BR>In terms of performance, the stock has underperformed the broader market, with a year-to-date decline of 24.24%, compared to a 14.70% drop in the Sensex. Over the past month, it has also seen a significant decline of 9.63%, while the sector itself, Pharmaceuticals & Drugs, has fallen by 3.62%. The falling investor participation is evident, as the delivery volume has decreased by 39.94% against the 5-day average.<BR><BR>Despite some positive factors, such as an attractive valuation and high institutional holdings at 27.18%, the overall outlook remains negative. The company has reported poor long-term growth, with operating profit declining at an annual rate of 8.16% over the last five years. Recent financial results have also shown a significant drop in profit after tax, down 31.1%, and the lowest cash and cash equivalents recorded at Rs 623.20 crore. These factors contribute to the stock's current decline.

Why is Jubilant Pharmova Ltd falling/rising?

As of 24-Mar, Jubilant Pharmova Ltd's stock price is rising to 862.15, driven by a trend reversal, strong sector performance, increased investor participation, and attractive valuations compared to peers. Despite a poor long-term growth outlook, recent profit increases have positively influenced investor sentiment.

As of 24-Mar, Jubilant Pharmova Ltd's stock price is rising, currently at 862.15, reflecting an increase of 47.95 (5.89%). This upward movement can be attributed to several factors. Notably, the stock has shown a trend reversal, gaining after three consecutive days of decline. Additionally, it outperformed its sector by 4.77% today, indicating a positive shift in investor sentiment.<BR><BR>The stock reached an intraday high of Rs 881.3, which is an increase of 8.24%. There has also been a significant rise in investor participation, with delivery volume on 23 March increasing by 67.66% compared to the 5-day average. This suggests that more investors are willing to hold the stock, which typically supports price increases.<BR><BR>Moreover, the stock is trading at a discount compared to its peers' average historical valuations, which may attract buyers looking for value. Despite a poor long-term growth outlook, as indicated by a -8.16% annual rate of operating profit growth over the last five years, the company's recent profit increase of 5.3% over the past year could be contributing to a more favorable perception among investors.<BR><BR>In summary, the combination of a trend reversal, strong sector performance, increased investor participation, and attractive valuation relative to peers are key factors driving the rise in Jubilant Pharmova Ltd's stock price.

Why is Jubilant Pharmova Ltd falling/rising?

As of 25-Mar, Jubilant Pharmova Ltd's stock price is rising to 864.85, reflecting a 0.67% increase. Despite short-term gains driven by increased investor interest, long-term growth prospects are concerning due to declining operating profits and negative financial results.

As of 25-Mar, Jubilant Pharmova Ltd's stock price is rising, currently at 864.85, reflecting a change of 5.75 (0.67%) upward. The stock has shown a positive trend over the last two days, gaining 6.22% during this period. Additionally, it reached an intraday high of Rs 886.5, which is a 3.19% increase. <BR><BR>Investor participation appears to be increasing, as evidenced by a delivery volume of 86.72k on 24 March, which is up by 16.39% compared to the 5-day average. This rising interest may contribute to the upward movement in the stock price. Furthermore, the stock is currently trading at a discount compared to its peers' average historical valuations, which may attract more investors looking for value.<BR><BR>However, it is important to note that despite the recent gains, the stock has underperformed its sector by 1.22% today and has a year-to-date decline of 19.53%. The long-term outlook remains concerning due to poor growth, with operating profit decreasing at an annual rate of -8.16% over the last five years. Additionally, recent negative results, including a significant drop in profit after tax and low cash reserves, could weigh on future performance. <BR><BR>In summary, while the stock is experiencing a short-term rise due to increased investor participation and attractive valuations, the long-term growth prospects are hindered by declining operating profits and recent negative financial results.

Which are the latest news on Jubilant Pharmo?